These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

562 related items for PubMed ID: 25015204

  • 1. Esophageal dose tolerance to hypofractionated stereotactic body radiation therapy: risk factors for late toxicity.
    Stephans KL, Djemil T, Diaconu C, Reddy CA, Xia P, Woody NM, Greskovich J, Makkar V, Videtic GM.
    Int J Radiat Oncol Biol Phys; 2014 Sep 01; 90(1):197-202. PubMed ID: 25015204
    [Abstract] [Full Text] [Related]

  • 2. Acceptable toxicity after stereotactic body radiation therapy for liver tumors adjacent to the central biliary system.
    Eriguchi T, Takeda A, Sanuki N, Oku Y, Aoki Y, Shigematsu N, Kunieda E.
    Int J Radiat Oncol Biol Phys; 2013 Mar 15; 85(4):1006-11. PubMed ID: 23102838
    [Abstract] [Full Text] [Related]

  • 3. Prediction of chest wall toxicity from lung stereotactic body radiotherapy (SBRT).
    Stephans KL, Djemil T, Tendulkar RD, Robinson CG, Reddy CA, Videtic GM.
    Int J Radiat Oncol Biol Phys; 2012 Feb 01; 82(2):974-80. PubMed ID: 21300453
    [Abstract] [Full Text] [Related]

  • 4. Predictors of toxicity associated with stereotactic body radiation therapy to the central hepatobiliary tract.
    Osmundson EC, Wu Y, Luxton G, Bazan JG, Koong AC, Chang DT.
    Int J Radiat Oncol Biol Phys; 2015 Apr 01; 91(5):986-94. PubMed ID: 25659885
    [Abstract] [Full Text] [Related]

  • 5. Stereotactic body radiotherapy for central lung tumors.
    Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH.
    J Thorac Oncol; 2012 Sep 01; 7(9):1394-9. PubMed ID: 22843088
    [Abstract] [Full Text] [Related]

  • 6. Predicting High-Grade Esophagus Toxicity After Treating Central Lung Tumors With Stereotactic Radiation Therapy Using a Normal Tissue Complication Probability Model.
    Duijm M, van der Voort van Zyp NC, van de Vaart P, Oomen-de Hoop E, Mast ME, Hoogeman MS, Nuyttens JJ.
    Int J Radiat Oncol Biol Phys; 2020 Jan 01; 106(1):73-81. PubMed ID: 31499137
    [Abstract] [Full Text] [Related]

  • 7. Local control and toxicity in a large cohort of central lung tumors treated with stereotactic body radiation therapy.
    Modh A, Rimner A, Williams E, Foster A, Shah M, Shi W, Zhang Z, Gelblum DY, Rosenzweig KE, Yorke ED, Jackson A, Wu AJ.
    Int J Radiat Oncol Biol Phys; 2014 Dec 01; 90(5):1168-76. PubMed ID: 25303891
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Radiation-induced rib fractures after hypofractionated stereotactic body radiation therapy of non-small cell lung cancer: a dose- and volume-response analysis.
    Pettersson N, Nyman J, Johansson KA.
    Radiother Oncol; 2009 Jun 01; 91(3):360-8. PubMed ID: 19410314
    [Abstract] [Full Text] [Related]

  • 10. Lung stereotactic body radiation therapy (SBRT) delivered over 4 or 11 days: a comparison of acute toxicity and quality of life.
    Jain S, Poon I, Soliman H, Keller B, Kim A, Lochray F, Yeung L, Cheung P.
    Radiother Oncol; 2013 Aug 01; 108(2):320-5. PubMed ID: 23993401
    [Abstract] [Full Text] [Related]

  • 11. Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer: a prospective study.
    Feddock J, Arnold SM, Shelton BJ, Sinha P, Conrad G, Chen L, Rinehart J, McGarry RC.
    Int J Radiat Oncol Biol Phys; 2013 Apr 01; 85(5):1325-31. PubMed ID: 23265574
    [Abstract] [Full Text] [Related]

  • 12. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma.
    Bradley J, Graham MV, Winter K, Purdy JA, Komaki R, Roa WH, Ryu JK, Bosch W, Emami B.
    Int J Radiat Oncol Biol Phys; 2005 Feb 01; 61(2):318-28. PubMed ID: 15667949
    [Abstract] [Full Text] [Related]

  • 13. Retrospective cohort study of bronchial doses and radiation-induced atelectasis after stereotactic body radiation therapy of lung tumors located close to the bronchial tree.
    Karlsson K, Nyman J, Baumann P, Wersäll P, Drugge N, Gagliardi G, Johansson KA, Persson JO, Rutkowska E, Tullgren O, Lax I.
    Int J Radiat Oncol Biol Phys; 2013 Nov 01; 87(3):590-5. PubMed ID: 24074933
    [Abstract] [Full Text] [Related]

  • 14. Stereotactic body radiotherapy for small hepatocellular carcinoma: a retrospective outcome analysis in 185 patients.
    Sanuki N, Takeda A, Oku Y, Mizuno T, Aoki Y, Eriguchi T, Iwabuchi S, Kunieda E.
    Acta Oncol; 2014 Mar 01; 53(3):399-404. PubMed ID: 23962244
    [Abstract] [Full Text] [Related]

  • 15. Dosimetric predictors of radiation-induced lung injury in stereotactic body radiation therapy.
    Ricardi U, Filippi AR, Guarneri A, Giglioli FR, Mantovani C, Fiandra C, Anglesio S, Ragona R.
    Acta Oncol; 2009 Mar 01; 48(4):571-7. PubMed ID: 19031164
    [Abstract] [Full Text] [Related]

  • 16. Vertebral compression fracture (VCF) after spine stereotactic body radiation therapy (SBRT): analysis of predictive factors.
    Cunha MV, Al-Omair A, Atenafu EG, Masucci GL, Letourneau D, Korol R, Yu E, Howard P, Lochray F, da Costa LB, Fehlings MG, Sahgal A.
    Int J Radiat Oncol Biol Phys; 2012 Nov 01; 84(3):e343-9. PubMed ID: 22658511
    [Abstract] [Full Text] [Related]

  • 17. Radiation-induced rib fractures after hypofractionated stereotactic body radiation therapy: risk factors and dose-volume relationship.
    Asai K, Shioyama Y, Nakamura K, Sasaki T, Ohga S, Nonoshita T, Yoshitake T, Ohnishi K, Terashima K, Matsumoto K, Hirata H, Honda H.
    Int J Radiat Oncol Biol Phys; 2012 Nov 01; 84(3):768-73. PubMed ID: 22445398
    [Abstract] [Full Text] [Related]

  • 18. Spine radiosurgery: a dosimetric analysis in 124 patients who received 18 Gy.
    Schipani S, Wen W, Jin JY, Kim JK, Ryu S.
    Int J Radiat Oncol Biol Phys; 2012 Dec 01; 84(5):e571-6. PubMed ID: 22975607
    [Abstract] [Full Text] [Related]

  • 19. Stereotactic body radiotherapy for patients with unresectable primary hepatocellular carcinoma: dose-volumetric parameters predicting the hepatic complication.
    Son SH, Choi BO, Ryu MR, Kang YN, Jang JS, Bae SH, Yoon SK, Choi IB, Kang KM, Jang HS.
    Int J Radiat Oncol Biol Phys; 2010 Nov 15; 78(4):1073-80. PubMed ID: 20207492
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.